Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$23.32 USD

23.32
417,034

+0.16 (0.69%)

Updated May 28, 2024 04:00 PM ET

After-Market: $23.31 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?

Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.

    Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?

    ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.

      Myriad Genetics Fortifies Molecular Diagnostics With FDA Nod

      Myriad Genetics (MYGN) has been leaving no stone unturned to boost the uptake of BRACAnalysis CDx test and strengthen the Molecular Diagnostics portfolio.

        AstraZeneca's Lynparza Label Now Includes Breast Cancer

        AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.

          Teleflex (TFX), HealthTrust Rebond on Respiratory Products

          Teleflex's (TFX) exclusive contracts with HealthTrust provide benefits to the latter with an opportunity to consolidate its members' respiratory purchases with the same supplier.

            Walgreens Closes PharMerica Buyout as KKR's Minority Partner

            Walgreens (WBA) along with privately-held global investment firm KKR completes the acquisition of Pharmerica for $1.4 billion. The merger agreement was announced in August.

              Myriad Genetics Presents Favorable EMBRACA Trial Results

              Myriad Genetics (MYGN) adopts initiatives to boost uptake of BRACAnalysis CDx test.

                Myriad Genetics Rides on Solid Molecular Diagnostics Suite

                Myriad Genetics (MYGN) adopts initiatives to boost the Molecular Diagnostics portfolio.

                  NuVasive (NUVA) to Acquire SafePassage, Strengthens IONM

                  NuVasive's (NUVA) combined entity with SafePassage seems strategic as the move will fortify the NuVasive Clinical Services' (NCS) status as the largest U.S. provider of outsourced IONM services.

                    Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory

                    Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.

                      Here's Why You Should Invest in Cooper Companies (COO) Now

                      Cooper Companies (COO) is consistently trying to boost inorganic growth.

                        Genomic Health (GHDX) Oncotype DX Score Test Data Positive

                        Genomic Health (GHDX) forges ahead with development of Oncotype DX Breast Recurrence Score test.

                          Boston Scientific Receives FDA Nod for Vercise DBS System

                          Boston Scientific (BSX) forges ahead with initiatives to boost DBS portfolio under Neuromodulation business.

                            Smith & Nephew's Rotation Medical Deal Aids Tissue Regen Arm

                            Smith & Nephew's (SNN) completion of Rotation Medical acquisition appears highly strategic as this will consolidate the company's position in disruptive technologies and advance its overall growth.

                              Hill-Rom (HRC) Banks on Strategic Buyouts, Competition Rife

                              Hill-Rom's (HRC) upbeat long-term view buoys optimism.

                                Inogen Rides on Solid Product Portfolio Amid Forex Woes

                                Inogen's (INGN) expanding product portfolio is a key catalyst. Foreign exchange headwinds continue to hurt the company's growth trajectory.

                                  Omnicell's Rising Costs Affect Bottom Line Amid Competition

                                  Soft margin scenario is a headwind for Omnicell (OMCL). The company's strategic endeavors such as portfolio expansion, acquisitions and new market growth persistently escalate expenses.

                                    Myriad Genetics Presents Encouraging EndoPredict Test Data

                                    Myriad Genetics (MYGN) forges ahead with initiatives to boost the Molecular Diagnostics portfolio.

                                      NxStage Nx2me Connected Health Improves Home Hemodialysis

                                      NxStage Medical (NXTM) consistently looks to expand dialysis platform.

                                        Cooper Companies (COO) Tops Q4 Earnings & Revenue Estimates

                                        Cooper Companies (COO) continues to witness impressive results at the CooperVision business segment that delivered strong sales in Q4.

                                          Vertex Kalydeco Study Successful in Children Aged 1-2 Years

                                          Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.

                                            Varian Halcyon Gets ANVISA Registration, Grows in Oncology

                                            Varian (VAR) consistently tries to expand in the global market with Halcyon system.

                                              Genomic Health-Janssen Pharma Tie Up, GPS Test in Focus

                                              Genomic Health (GHDX) focuses on notable partnerships to promote its Oncotype DX Genomic Prostate Score (GPS) test.

                                                Myriad Genetics (MYGN) Presents Positive riskScore Test Data

                                                Myriad Genetics (MYGN) presents positive riskScore data at the SABCS. With riskScore, the company intends to boost its myRisk Hereditary Cancer test suite.

                                                  Hologic's Panther Fusion Flu AdV/hMPV/RV Assay Wins FDA Nod

                                                  Hologic's (HOLX) recent spree of regulatory approvals for its array of products is encouraging.